The regulation of insulin release from pancreatic beta cells is a highly complex process, integrating glycaemia value as well as the modulatory actions of many hormones, neuropeptides and neurotransmitters [1] . The endocrine pancreas is richly innervated by sympathetic neurons and electrical stimulation of splanchnic nerves or treatment with epinephrine results in strong inhibition of insulin secretion [2] . Pharmacological studies carried out both in vivo [3±4] and on isolated islets [5] show that this inhibitory effect is primarily due to stimulation of peripheral adrenoceptors of the a 2 -type. Consistent with this, binding studies with selective radioligands showed the presence of a 2 -adrenoceptors on membranes from pancreatic islets isolated from various species [6] as well as on membranes from a rodent insulinoma [7] . The a 2 -adrenoceptor family consists of three receptor subtypes (a 2A , a 2B and a 2C ) encoded by distinct genes that do not have introns [8] . Transcripts encoding a 2A -and a 2B -subtypes were detected recently in human [9] and rat [10] pancreatic islets. On the basis of functional studies, the a 2A -subtype is, however, responsible for inhibition of insulin secretion [11±12]. Diabetologia (2000) 
It is thus generally accepted that the hyperglycaemic response to a 2 -agonists is mainly due to the inhibition of insulin secretion through stimulation of postsynaptic a 2A -adrenoceptors located on beta cells.
It has also been suggested that catecholamines and a 2 -adrenoceptors are involved in the aetiology and pathogenesis of Type II (non-insulin-dependent) diabetes mellitus, which is characterised by an impaired insulin response to glucose challenge. The plasma concentrations of catecholamines are higher in diabetic than in healthy subjects [13±14] and glucose intolerance is frequently observed in patients with pheochromocytoma [15±16] . Furthermore, islets isolated from rats that had received neonatal streptozotocin injections (a model of Type II diabetes) were more sensitive to a 2 -adrenergic inhibition of glucoseinduced insulin release than islets from controls [17±18] . Hence it has been postulated that, in some diabetic patients, insulin secretion is pathologically restrained because of increased tonic inhibition by a 2 -adrenoceptors. Subsequently, a 2 -blockers were viewed as potentially useful adjuncts in the management of Type II diabetes and compounds such as phentolamine, MK912 and SL 84.0418 were shown to be efficient hypoglycaemic agents [19±21] . The precise physiological role of the beta-cell a 2 -adrenoceptors in the regulation of insulin secretion is, however, still a matter of discussion. Pharmacologic data in isolated islets are difficult to interpret because there is a possibility that in islets (nor)adrenaline or alpha-agonists influence presynaptic intraislet nerve endings [22] . Moreover, noradrenaline not only affects insulin release but also glucagon and somatostatin secretion, creating a complex paracrine situation. Furthermore, beta-cell lines might not be a good alternative for whole islets because among the several possible different alpha 2-receptor subtypes that have been cloned, an expression pattern for normal beta cells distinct from that of beta tumour cells has been described [23] . Nevertheless, the study of a 2 -adrenoceptors on purified rat beta cells in vitro has shown that a 2 -adrenoceptors are important for glucose-induced insulin release [24] . Results from studies in vivo are also difficult to interpret because of the concomitant effects of a 2 -adrenergic compound infusion on other neuroendocrine functions and islet blood supply, which might also affect insulin secretion. For instance, the enhancement of insulin secretion after yohimbine treatment was reduced after vagotomy and abolished by b-antagonists, indicating that activation of cholinergic and noradrenergic systems is involved in the effect of this non-imidazoline a 2 -antagonist [25] . The contribution of a 2 -adrenoceptor blockade to the restoration of insulin secretion in Type II diabetes is also controversial. The a 2 -antagonists of the imidazole family (such as phentolamine, idazoxan and efaroxan) are more potent insulinotropic agents than yohimbine and able to reverse the effect of diazoxide [26] . The greater efficacy of imidazoline-derivatives is the consequence of blockade of K + conductance through their direct interaction with the pore-forming subunit Kir6.2 of ATP-sensitive K + channels [27] . We examined the role of pancreatic a 2A -adrenoceptors in the regulation of insulin secretion by developing transgenic mice overexpressing this receptor subtype in their beta cells. Metabolic studies of this animal model indicate that increased a 2 -adrenergic receptivity leads to an exacerbated hypoinsulinaemic response to a 2 -agonist and to development of glucose intolerance.
Materials and methods
Construction of the human insulin promoter/human a 2 C10 adrenoceptor chimeric gene (hInsp/a 2 C10) and generation of transgenic mice. The hInsp/a 2 C10 transgene consists of a 2 kb fragment of human insulin promoter fused to the coding region of the human a 2A -adrenoceptor gene. This construct was obtained as follows: the NheI-HindIII fragment (2 kb) of the a 2 C10 gene containing the entire open reading frame of the human a 2A -adrenoceptor [28] was engineered to create EcoRI sites at each end. This EcoRI/EcoRI fragment was then inserted in a new EcoRI subcloning site engineered to destroy the ATG translation start site [29] in the BamHI-XhoI fragment (4.6 kb) of the human insulin gene [30] . The general procedure for generation of transgenic mice was as described previously [31] . Briefly, the BamHI-XhoI fragment (6.6 kb, Fig. 1 ) containing the entire chimeric gene was purified and microinjected into fertilised eggs obtained from superovulated C57BL6/SJL mice, and viable embryos were reimplanted in the oviducts of pseudopregnant mice. The presence of the transgene was tested by Southern blot analysis. Genomic DNA (10 mg) isolated from tail biopsy specimens of 3-week-old animals were digested with EcoRI. Fragments of DNA were separated by agarose gel electrophoresis, blotted and hybridised to a [ 32 P]-labelled cDNA probe prepared from the NheI-HindIII fragment of the a 2 C10 gene. There was no cross-reactivity of this probe with genomic DNA from control mice.
Treatment of animals and determination of hormone and metabolite concentrations. Transgenic mice used were heterozygous for the hInsp/a 2 C10 construct. Control and transgenic mice were fed standard mouse chow (Panlab, Barcelona, Spain), given free access to water and kept under a light-dark cycle of 12 h (light on at 0800 hours). The animals were handled according to the ªPrinciple of Laboratory Animal Careº (NIH publication no. 85±23, revised 1985). All experiments were carried out on 2 to 4-month-old animals between 0900 and 1100 hours to minimize circadian variations, a 2 -adrenergic drugs were dissolved in saline and given by intraperitoneal injection. Serum insulin concentrations were measured by radioimmunoassay (RIA) (CIS, Biointernational, Gif-Sur-Yvette, France). Serum glucose concentration was measured either enzymatically (Glucoquant, Boehringer Mannheim, Mannheim, Germany) or by using a Glucometer Elite analyser (Bayer, Tarrytown, N. Y., USA). To quantify pancreatic insulin content, whole pancreas was removed from the mice and insulin was extracted by mechanical homogenisation of the organ in 20 vols of cold acid ethanol (75 % ethanol, 1.5 % concentrated HCl) followed by 48 h of agitation at 40°C. After centrifugation, insulin was quantified in the supernatants of the samples by RIA (CIS, Biointernational).
Glucose and insulin tolerance tests. Control and transgenic mice fasted overnight (16 h) with free access to water were anesthetised with an intraperitoneal injection of 2.5 % avertin solution. They were then given an intraperitoneal injection of either saline or glucose (1 g/kg of body weight). The 2-(2-methoxy-1,4-benzodioxan-2-yl)-2-imidazoline (RX821 002) antagonist (10 mmol/kg) was injected 30 min before glucose injection. Blood samples (2 ml) were obtained from tail vein before the glucose injection and at several time points after the glucose load. For the intraperitoneal insulin tolerance test, fed control and transgenic mice were anaesthetised and afterwards injected intraperitoneally with 0.75 IU of a soluble insulin (Humulin regular, Eli Lilly, Indianapols, Ind., USA) per kg body weight. Blood samples were taken from the tail vein of the same animals at several time points and glucose concentration measured.
Immunohistochemical analysis. For immunohistochemical detection of insulin and glucagon, pancreas from control and transgenic mice were fixed for 12 to 24 h in formalin, embedded in paraffin and sectioned. Sections were then incubated overnight at 4°C with a guinea pig anti-porcine insulin antibody (Dako, Carpinteria, Calif., USA), at 1:100 dilution, or with a rabbit anti-human glucagon antibody (ICN, Costa Mesa, Calif., USA) in 1:4000 dilution. Rabbit anti-guinea pig immunoglobulin G, coupled to peroxidase (Boehringer Mannheim), or biotinylated goat anti-rabbit antibody and ABC complex (Vector, Burlingame, Calif., USA) were used as secondary antibodies. As the substrate chromogen 3'3'-diaminobenzidine (DAB) was used. Sections were counterstained in Mayer's haematoxylin (Merck, Darmstadt, Germany).
Preparation of pancreatic islets. Islets were isolated from the pancreas of control and transgenic mice (2-month-old) fed a standard diet. They were released from pancreatic acinar tissues by digestion with collagenase P (Boehringer Mannheim) and collected by handpicking under a dissection microscope as described previously [32] .
RNA analysis. Islet total RNA was extracted by using the guanidine isothiocyanate method [33] . Expression of the transgene was assessed by RT-PCR. First strand cDNA synthesis was done using 1 mg RNA in a 100 ml reaction volume containing ng 1000 U Moloney mouse leukaemia virus reverse transcriptase (Perkin Elmer, Norwalk, Conn., USA) and 0.5 mmol/ l oligodT in conditions recommended by the manufacturer. After 1 h at 37°C the reaction was stopped by 5 min treatment at 95°C. We amplified cDNA by PCR in a 25 ml reaction volume containing 1 U Taq polymerase (Boehringer Mannheim), 0.25 mmol/l of sense and antisense primers, 0.2 mmol/l deoxyribonucleoside triphosphate (dNTP), 10 mmol/l TRIS-HCl, 3 mmol/l MgCl 2 , 10 % dimethyl sulphoxide (DMSO) and 2.5 % formamide. After 3 min at 94°, the reaction mixture was subjected to 40 cycles of denaturation, hybridation and elongation as follows : 15 s at 940, 30 s at 60, 1 min at 72. The sense primer (5 ¢-GGACAGGCTGCATCAGAA-GAGG-3 ¢) was located in the first exon of the human insulin gene and the antisense primer (5 ¢-GGCACACCAGCGT-CAGCGTCAC-3 ¢) was specific for the a 2 C10 gene. Amplification of the genomic DNA gave a band of 527 bp whereas amplification of the cDNA gave a band of 366 bp.
Receptor quantification. We quantified a 2 -adrenoceptors on crude membrane preparations using the a 2 -antagonist [ 3 H]RX821 002 as a radioligand [34] . Frozen islets from control and transgenic mice were thawed directly in 5 ml of TE buffer (50 mmol/l TRIS-HCl, pH = 7.5, 5 mmol/l EDTA), disrupted using a Dounce homogeniser, and centrifuged at 25000 g for 10 min. The pellet was washed in TM buffer (50 mmol/l TRIS-HCl, 0.5 mmol/l MgCl 2 , pH 7.5) in the same conditions as above. The final crude membrane fraction was taken in the appropriate volume of TM buffer for immediate use. The amount of membrane necessary for each binding point corresponded to that obtained from approximately 40 islets. The protein concentration was measured using Bradford's method [35] . Total binding was measured by incubating 100 ml of islet membranes with [ 3 H]RX821 002 (0.5 to 8 nmol/l) in a total volume of 400ml of TM buffer. After a 45-min incubation at 25°C, bound radioligand was separated from free by passage through GF/C Whatman filters using a cell harvester (Skatron Instruments, Lier, Norway). After washing in ice-cold TM buffer, membrane-bound radioactivity was determined by liquid spectrometry. Specific binding was defined as the difference between total and non-specific binding measured in the presence of 10 mmol/l phentolamine. Data from binding experiments were analysed using the EBDA-ligand computer program [36] Measurement of insulin secretion from isolated islets. Batches of six islets were incubated in 1 ml of Krebs-Ringer bicarbonate buffer supplemented with 5 mg/ml BSA (Fraction V, Sigma, St. Louis, Mo., USA) and various concentrations of glu- transgene expression in mouse pancreatic islets. Approximately 1 mg of total RNA prepared from isolated islets was reverse transcribed and then subjected to a nested PCR using specific primers as indicated in Methods. Lanes M, 100 bp DNA ladder; lane PL, direct PCR from hInsp/a 2 C10 construct ; lane C, RT-PCR from RNA prepared from control mouse and lanes 1 to 5, RT-PCR from RNA prepared from transgenic mice cose (2.8, 5.5, 11.1 or 16.7 mmol/l). Experiments were carried out in the absence or presence of 10 nmol/l of the a 2 -agonist 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline (UK14 304). After incubation for 1 h at 37 C, tubes were centrifuged and supernatants were stored at ±20 C until the measurement of insulin content by RIA.
Statistical analysis. All values are expressed as the means ± SEM. Statistical analysis was carried out using the StudentNewmann-Keuls test and significance was accepted at the over 95 % confidence level.
Results
Expression of the hInsp/a 2 C10AR transgene. Transgenic mice containing an hInsp/a 2 C10AR chimeric gene were developed to specifically target overexpression of the a 2A -adrenoceptor to beta cells of pancreatic islets. Of the progeny born mouse oocytes were injected, five transgenic founders containing the construct were identified by Southern blot analysis (data not shown). All these founders were successfully bred to establish transgenic lines and RT-PCR analysis was done on RNA isolated from islets. The specific primers chosen for this purpose allowed us to amplify a 366 bp fragment in the endocrine pancreas of three of the transgenic lines (Tg1, Tg3 and Tg4) (Fig. 1) . No signal was detected either in control animals or in the other two transgenic lines. Estimation of a 2 -adrenoceptor number by measuring radioligand binding was thus restricted to these three transgenic lines expressing the chimeric gene. Analysis of the saturation isotherms of [ 3 H]RX821 002 binding to crude membranes prepared from isolated islets showed that the Tg1 transgenic line had a ninefold higher a 2 -adrenoceptor density than control (119 ± 17 vs 13 ± 4 fmol/mg protein) (Fig. 2) . No statistically significant increase in the binding capacity was, however, detected in islet membranes from Tg3 or Tg4 transgenic mice compared with controls (data not shown). This indicated that although these transgenic mice expressed the transgene, the concentrations of the protein were probably low. Neither the presence of hInsp/a 2 C10AR transcript nor an increase in a 2 -adrenoceptor density was observed in the other tissues examined (spleen, brain cortex, kidney), indicating that overexpression of a 2 -adrenoceptor was restricted to pancreatic islets. Further studies of the pharmacological properties of the a 2 -adrenoceptor in islets of Tg1 transgenic mice showed that yohimbine was 5000-fold more potent than prazosin in inhibiting [ 3 H]RX821 002 binding (data not shown), meaning that the overexpressed receptor was of the a 2A -subtype. Immunohistological analysis showed that neither the size and number, nor the respective proportion of insulin-containing and glucagon-containing cells was changed in transgenic islets (data not shown). All subsequent experiments were carried out on 2 to 3-month-old heterozygous Tg1 transgenic mice. Non-transgenic littermates were used as controls.
Serum variables and insulin secretion by isolated islets.
No difference in insulinaemia and glycaemia was observed between transgenic and control mice under basal conditions (Fig. 3) . A single intraperitoneal injection of the a 2 -agonist UK14 304 (1 mmol/kg of body weight) led, however, to an about twofold increase in blood glucose concentration in control animals. As expected for an a 2 -agonist, this hyperglycaemic effect correlated with a moderate inhibition of insulinaemia (35 % decrease). The effects of UK14 304 were exacerbated in transgenic mice, which had a 3.5-fold increase in glycaemia and a more pronounced decrease in insulinaemia (76 %).
Studies of the functional response of isolated islets to the a 2 -agonist were carried out to determine whether the decrease in serum insulin concentrations correlated with alteration of insulin secretion. Pancreatic islets were thus isolated from fed control and transgenic mice and insulin release was measured at several glucose concentrations in the presence or the absence of 10 nmol/l UK14 304. In the absence of the a 2 -agonist, insulin secretion by transgenic islets was identical to that of controls (Fig. 4) . At the highest concentration of glucose tested (16.7 mmol/l) an equal induction of insulin secretion (2.5-fold in control vs 2.6-fold in transgenic) was observed, indicating that the secretory response of the islet to glucose was not affected by a 2 -adrenoceptor overexpression. Thus, this suggests that signalling induced by glucose is not tonically affected by a 2 -adrenoceptors in isolated islets. In contrast, a pronounced difference in the profiles of insulin secretion was detected when UK14 304 was added to the incubation medium. The a 2 -agonist caused a decrease in insulin secretion whatever the concentration of glucose tested but this effect was significantly greater on islets from transgenic mice exposed to a high glucose concentration (63 % decrease in transgenic vs 40 % in control at 16.7 mmol/l glucose) (Fig. 4) . Measurements of islet glycolysis at three glucose concentrations (2.8, 5.5 and 16.7 mmol/l) in the presence of UK14 304 were also done. No difference was found between control and transgenic islets (data not shown), suggesting that the difference in insulin secretion in the presence of a 2 -agonist was probably not dependent on further decrease in glucose utilisation. In addition, no difference was noted in pancreatic insulin content between control and transgenic mice (7.1 0.3 mg/100 mg pancreas vs 6.4 0.5 mg/100 mg pancreas), indicating that a 2 -adrenoceptor overexpression did not affect betacell growth or differentiation.
Glucose and insulin tolerance tests. Glucose tolerance tests were carried out to assess whether the differences observed in isolated islets could lead to an alteration of glucose homeostasis after an intraperitoneal glucose load. Glycaemia in starved control animals was nearly the same as in starved transgenics (respectively, 5.7 ± 0.3 and 6.4 ± 0.4 mmol/l). Furthermore, at the different time points after intraperitoneal injection of saline solution both control and transgenic mice had similar blood glucose concentrations (30 min, 6 ± 0.3 vs 6.2 ± 0.2 mmol/l; 60 min, 6.2 ± 0.3 vs 5.9 ± 0.4 mmol/l; 120 min, 6.4 ± 0.4 vs 6.4 ± 0.4 mmol/l). This indicated that handling of animals with the repeated tail snipping in itself did not affect blood glucose concentrations. Intraperitoneal injection of glucose also resulted in a similarily rapid increase of glycaemia (14.2 ± 0.9 mmol/l in control vs 15.3 ± 0.7 mmol/l in transgenic, 30 min after injection) (Fig. 5) . Although blood glucose concentration returned to the basal value within 180 min after load in control mice, glycaemia was still high in transgenic mice (12.2 mmol/l). This inability to reduce the concentration of blood glucose suggested that transgenic mice expressing the chimeric gene were glucose intolerant. To establish whether the alteration in glucose tolerance test was exclusively due to a 2 -adrenoceptor Data represent means ± SEM of 12 to 15 mice per group (* p < 0.05, ** p < 0.02) Fig. 4 . Effect of UK14 304 on insulin secretion from isolated islets. Batches of six islets from control and transgenic mice were incubated for 1 h in Krebs-Ringer bicarbonate buffer containing 2.8, 5.5, 11.1 or 16.7 mmol/l glucose. Insulin secretion was measured in the absence or presence of 10 nmol/l UK14 304. Data are presented as means ± SEM of eight individual experiments. * and ** indicate values significantly different from the corresponding in control animals at p < 0.05 and p < 0.02. k control, U Tg1, A control + UK 14304, R Tg1 + UK 14304 overexpression, the same experiments were done in the presence of a 2 -antagonist RX821 002. Treatment with of RX821 002 before intraperitoneal injection of glucose totally abolished the difference between transgenic and control mice (Fig. 5) . Furthermore, restoration of normoglycaemia was faster in mice treated with antagonist than in untreated controls. The differences between the four groups are even more evident when the results are expressed as the increase in area under the curve (Fig. 5 ). All these findings indicate that overexpression of a 2 -adrenoceptors in beta cells induces alterations in glucose tolerance.
When an intraperitoneal insulin tolerance test (injection of 0.75 IU/kg body weight of soluble insulin (Humulin regular, Eli Lilly)) was done in fed mice, a similar hypoglycaemic response was, however, observed in transgenic and in control mice. Thus, by 60 min, both control and transgenic mice showed a 40 % decrease in blood glucose concentrations (Fig. 6 ), indicating that transgenic mice overexpressing a 2 -adrenoceptors in beta cells show altered islet function rather than reduced insulin sensitivity. Therefore, because transgenic mice had normal insulin sensitivity but showed impaired glucose-stimulated insulin secretion in vivo and normal glucosestimulated insulin secretion in vitro, our study suggests a possible tonic influence of a 2 -adrenoceptors in vivo.
Discussion
Several lines of evidence have shown that epinephrine and norepinephrine play a major part in the negative regulation of insulin secretion. The antisecretagogue effect of catecholamines is primarily triggered by the stimulation of a 2 -adrenoceptors located on beta cells and it has even been suggested that an increased sympathetic innervation or a reinforced a 2 -adrenergic response of pancreatic islets or both accounts for the impaired secretory response to glucose observed in certain forms of Type II diabetes. The effect of sympathetic hyper-innervation has been studied in a transgenic mouse in which overexpression of nerve growth factor (NGF) was specifically targeted to beta cells [37] . Surprisingly, these mice have nor- Results are means ± SEM of seven transgenic ±*± and seven control (±A±) mice mal regulation of glycaemia. Moreover, their islets showed enhanced insulin secretion in response to glucose and blunted response to the a2-antagonist, phentolamine, suggesting that the lack of incidence of hyper-innervation was primarily due to a 2 -adrenoceptor desensitisation [38] . We reinvestigate the putative role of pancreatic a 2 -adrenoceptors in the emergence of Type II diabetes by developing an animal model that overexpresses this receptor in beta cells.
The use of a chimeric gene containing the human insulin promoter fused to the a 2 C10AR gene allowed us to obtain a transgenic mouse line in which a 2 -adrenoceptor density in pancreatic islets was ninefold higher than in controls. Analysis of this model indicated that receptor overexpression did not cause any modification of insulinaemia or glycaemia. As already suggested [39] , this lack of effect could be because the sympathetic system does not exert any tonic inhibition on insulin secretion under resting conditions. The possibility that compensatory mechanisms against the overexpression of the a 2A -adrenoceptor operate in these transgenic mice cannot, however, be ruled out. Injection of a 2 -agonist UK14 304 into control mice resulted in a 35 % decrease in insulinaemia, whereas a 76 % decrease was noted in transgenic mice. Thus, the extent of the insulin and glycaemic responses to UK14 304 treatment was much higher in transgenic animals. The amplitude of the hyperglycaemic and hypoinsulinaemic response to UK14 304 in control mice is consistent with that reported for this imidazoline compound [40] . Moreover, these effects are exclusively due to being occupied by agonists because of a 2 -adrenoceptor they were efficiently blocked by non-imidazoline a 2 -antagonists such as rauwolscine [40] . According to the experiments carried out on isolated islets, the reinforced action of the a 2 -agonist in vivo in transgenic mice was probably the consequence of enhanced inhibition of insulin secretion. The molecular mechanisms by which a 2 -adrenoceptors inhibit insulin release from beta cells are not understood. Several pertussis toxin-sensitive mechanisms, including inhibition of adenylyl cyclase, opening of ATP-sensitive K + channels and inhibition of L-type Ca ++ channels contribute to the effect of a 2 -agonists [41, 42] . Moreover, control of the late steps in the pathway of insulin vesicle exocytosis has also been shown [41, 42] . A recent study on insulinoma cells transfected with the cDNA encoding mouse a 2A -adrenergic receptor suggested that receptor overexpression reduces cellular insulin content and attenuates basal and stimulated insulin secretion [43] . In contrast, here we found that the glucose-stimulated insulin secretion was similar in islets isolated from control and transgenic mice. A stronger decrease in insulin release by transgenic islets than in control was, however, observed in the presence of the a 2 -agonist. This indicates that receptor overexpression probably affects insulin secretion rather than insulin synthesis. Notably, intraperitoneal injection of glucose resulted in the emergence of glucose intolerance in transgenic mice. The difference between transgenic and control mice was not observed after injection of a 2 -antagonist RX821002, suggesting it is primarily the consequence of enhanced a 2 -adrenoceptor-mediated inhibition of insulin secretion after glucose injection. It is also of note that restoration of normoglycaemia was faster in RX821002-treated mice. The reason for this effect could be due to exclusive blockade of the a 2 -adrenoceptors indicating that in spite of anesthesia the mice were undergoing stress because of repeated tail snipping. After intraperitoneal injection of saline solution control and transgenic mice both, however, showed similar blood glucose concentrations. Alternatively, this effect could be the consequence of the use of RX821 002. At the concentration used in our study (10 mmol/kg), this imidazoline derivative is able to stimulate insulin secretion by a mechanism independent from interaction with a 2 -adrenoceptors [44] and involving binding to imidazoline sites and blockade of ATP-sensitive K + channels [45] .
The results obtained on this new model of transgenic mice show that a direct increased expression of a 2 -adrenoceptors in beta cells can cause alterations in the regulation of insulin secretion, resulting in intolerance to glucose. This is consistent with previous studies reporting enhanced pancreatic a 2 -adrenergic receptivity in rodent models of Type II diabetes and thus suggests that increased expression of inhibitory receptors could contribute to the aetiology of certain forms of this disease.
